Lixte Biotechnology Announces a Clinical Trial Agreement with Moffitt Cancer Center to Initiate Phase 1b/2 Trial Evaluating the Safety and Efficacy of LB-100 in Treatment of Patients with Low or Intermediate-1 Risk Myelodysplastic Syndrome
E-Power Resources Inc. Announces Tetepisca Flake Graphite Property Delivers High-Value Concentrate Potential, Demonstrating High Recoveries and Premium Flake Size Distribution
